Welcome to our dedicated page for Teva Pharm news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharm stock.
Teva Pharmaceutical Industries Ltd. (TEVA) is a global leader in generic medicines and biosimilars, delivering cost-effective healthcare solutions across 60+ countries. This dedicated news hub provides investors and professionals with verified updates on Teva’s strategic initiatives, regulatory milestones, and market developments.
Find official press releases, earnings reports, and analysis covering Teva’s core operations in generics manufacturing, innovative therapies, and active pharmaceutical ingredients (APIs). Our curated feed includes updates on FDA approvals, partnership announcements, patent developments, and sustainability initiatives impacting the pharmaceutical sector.
Bookmark this page to monitor Teva’s progress in biosimilar innovation, supply chain expansions, and responses to industry trends. All content is sourced from verified channels to support data-driven decisions in the evolving healthcare landscape.
Teva Pharmaceutical Industries Ltd. reported Q4 2021 revenues of $4.1 billion and full-year revenues of $15.9 billion, both showing declines from the previous year. Q4 GAAP diluted EPS was $(0.14), while non-GAAP diluted EPS rose to $0.77. For 2022, Teva forecasts revenues between $15.6 billion and $16.2 billion, with expected non-GAAP EPS of $2.40 - $2.60. The company anticipates growth from key products AUSTEDO® and AJOVY® and aims to advance FDA approval for Risperidone LAI, while resolving opioid litigation in Texas.
Teva Pharmaceuticals has settled opioid-related claims with the Texas Attorney General, agreeing to pay $150 million over 15 years and provide $75 million worth of generic Narcan over 10 years. While Teva admits no wrongdoing, CEO Kåre Schultz emphasizes the importance of expanding access to life-saving medications. The deal is seen as a crucial step in addressing the opioid crisis, although Teva will continue to defend itself in ongoing litigation in other states.
Teva Pharmaceuticals, in collaboration with Morehouse School of Medicine, released a national survey highlighting significant healthcare access challenges exacerbated by the COVID-19 pandemic. The survey indicates that 50% of consumers postponed or canceled healthcare services, with 64% of BIPOC groups affected. The report notes a rise in mental health diagnoses, with 84% of physicians observing increases since the pandemic. While 58% of consumers are likely to use telehealth post-pandemic, access remains a concern, particularly for low-income patients.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will release its fourth quarter and full year 2021 financial results, alongside financial guidance for 2022, on February 9, 2022, at 7:00 a.m. ET. A conference call and live webcast will follow at 8:00 a.m. ET. Investors can join the call by dialing specific numbers for the U.S., Israel, and international participants. A replay will also be available. Teva, a leader in generic and specialty medicines, has a portfolio of over 3,500 products, impacting 200 million patients globally.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced that its President & CEO, Kåre Schultz, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, starting at 9:45 A.M. Eastern Time. Investors can access a live webcast of the event via Teva's Investor Relations website. An archived version will be available within 24 hours and accessible for 30 days. With over 3,500 products, Teva is a global leader in generic and specialty medicines, improving lives for over a century.
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announces plans to appeal a recent unfavorable legal ruling regarding opioid prescriptions. The company argues that the plaintiffs failed to provide evidence of wrongdoing, including medically unnecessary prescriptions or harm caused by Teva's actions. Teva emphasizes its commitment to increasing access to essential medicines and is pursuing a national settlement. Recent court rulings in California and Oklahoma have found no evidence of public nuisance related to Teva's opioid marketing practices.
Teva Pharmaceutical Industries has launched a first-to-market generic version of Narcan® (naloxone hydrochloride nasal spray) in the United States. This prescription medicine addresses opioid emergencies like overdoses, allowing for immediate intervention. Teva boasts the largest portfolio of FDA-approved generic products, with nearly 550 available, and holds a leading position in first-to-file opportunities, with around 100 pending in the U.S. Currently, 1 in 12 generic prescriptions in the U.S. is for a Teva generic, enhancing its market presence.
Teva Pharmaceuticals has launched an authorized generic of Epiduo® Forte Gel (adapalene and benzoyl peroxide) in the United States, enhancing its portfolio of generic medicines. This topical treatment for acne vulgaris is notable as it is the first authorized generic for this product in the U.S. Epiduo® Forte Gel generated annual sales of $253 million in the U.S. as of September 2021. Teva holds the largest portfolio of FDA-approved generic products with nearly 550 medications available and around 100 pending first-to-files in the U.S.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced an increase in its tender offers' total maximum amount from
Teva Pharmaceuticals presented interim results from the FINESSE study at the German Society of Neurology (DGN) Congress 2021. The study evaluates the effectiveness of fremanezumab in chronic and episodic migraine patients. Data from 574 patients indicated a 48.7% achievement of the primary endpoint—a ≥ 50% reduction in migraine days after 6 months. Additionally, significant reductions in migraine days, disability scores, and acute medication use were observed. Overall, these findings align with previous Phase III studies and highlight fremanezumab's effectiveness in real-life settings.
